Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy

This study is testing a drug called ivonescimab for people with pleural mesothelioma — a rare and aggressive cancer that lines the chest cavity, often linked to asbestos exposure. Ivonescimab is a dual-action antibody that targets both the immune checkpoint (PD-1) and blood vessel growth (VEGF) to attack cancer from two angles at once. **You may be eligible if...** - You have been diagnosed with pleural mesothelioma confirmed by a surgical biopsy (thoracoscopy recommended) - You have not received prior systemic treatment for mesothelioma - Your general health (ECOG) is adequate - You have measurable disease on scans **You may NOT be eligible if...** - Your diagnosis was made only by fluid cytology (not a proper tissue biopsy) - You have had prior cancer treatments for mesothelioma - You have serious autoimmune or cardiac conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.